Reversal of central anticholinergic syndrome in man by physostigmine.
D000368:Aged; D001259:Ataxia / Q000139:chemically induced / Q000188:drug therapy; D002493:Central Nervous System Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D002648:Child; D003072:Cognition Disorders / Q000139:chemically induced / Q000188:drug therapy; D003693:Delirium / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D006212:Hallucinations / Q000139:chemically induced / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009388:Neostigmine / Q000009:adverse effects; D010276:Parasympatholytics / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy; D010830:Physostigmine / Q000627:therapeutic use*; D011229:Preanesthetic Medication; D012601:Scopolamine / Q000009:adverse effects; D013064:Speech Disorders / Q000139:chemically induced / Q000188:drug therapy; D014282:Trihexyphenidyl / Q000009:adverse effects
D010276:Parasympatholytics; D009388:Neostigmine; D014282:Trihexyphenidyl; D010830:Physostigmine; D012601:Scopolamine